Letter by Hoeper and Galié Regarding Article, “Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-I Study”

To the Editor:

We read with interest the article by Chen et al., which addressed an interesting new therapeutic strategy for patients with pulmonary hypertension, but at the same time, raised several issues on the conduct of this study. Most importantly, we have serious concerns about the withdrawal of targeted therapies for investigative reasons, and we question whether this approach was ethical, as these therapies improve symptoms and outcomes, at least in patients with pulmonary arterial hypertension. In addition, we take issue with the authors claiming that their procedure improved survival. There was no control group, and the reported 12% all-cause mortality after 1 year was higher than in most contemporary series. Although unproven, it is possible that some of these deaths might have been related to the withdrawal of effective therapies.

The article contains additional flaws, including an incorrect classification of pulmonary hypertension (World Health Organization group II pulmonary arterial hypertension does not exist), and baseline medications that do not meet current standards of care (in particular, the use of prostacyclin analogues in 89% of patients with pulmonary hypertension caused by left heart disease).

Novel therapeutic concepts for pulmonary hypertension are always embraced, and pulmonary artery denervation might be a promising new strategy that deserves careful investigation. Ideally, randomized, controlled, multicenter studies involving centers specialized in the care of patients with pulmonary hypertension should follow next.

Disclosures

Dr Hoeper has received fees for lectures and consultations from Actelion, Bayer, Gilead, GSK, and Pfizer. Dr Galié has received grant support and personal fees from GlaxoSmithKline, Actelion, Bayer, and Pfizer.

References

Letter by Hoeper and Galiè Regarding Article, "Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study"

Marius M. Hoeper and Nazzareno Galiè

doi: 10.1161/CIRCINTERVENTIONS.115.003422

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/9/1/e003422